Travere Therapeutics Pays $112.5M Upfront for 'Best-in-Class' Kidney Disease Drug, Up to $1.03B in Milestones
Summary
Travere Therapeutics has entered into an exclusive licensing agreement with Everest Medicines for civorebrutinib, a potential best-in-class BTK inhibitor for rare kidney diseases. Travere will pay an upfront fee of $112.5 million and up to $1.03 billion in additional milestone payments, plus tiered royalties. This follows a previous news report that Travere secured rights to the drug, now providing the critical financial terms. This deal significantly expands Travere's pipeline with a promising asset that could address multiple immune-mediated kidney diseases, including PMN, IgA nephropathy, FSGS, and MCD. The substantial financial commitment underscores the strategic importance of this acquisition for Travere's focus on rare renal therapies.
At the time of this announcement, TVTX was trading at $45.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $13.88 to $48.61. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Asian Corporate Newswire.